Haematopoietic growth factor

Phase 3Small molecule

Haematopoietic growth factor is one of 10 small molecule programs targeting Hodgkin Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hodgkin LymphomaRecruiting

Hodgkin LymphomaPhase 3

Recruiting

Competition

Competitive Landscape

10 competitors in Hodgkin Lymphoma

#DrugCompanyPhaseTrials

DTIC-Dome

Bayer

Phase 3

8 2

Opdivo

Bristol-Myers Squibb

Phase 3

8 3

Adcetris

Pfizer

Phase 3

7 4

Velban

Eli Lilly

Phase 3

5 5

Adriamycin

Pfizer

Phase 3

4 6

Adriamycin

Pfizer

Phase 3

4 7

Keytruda

Merck & Co.

Phase 2

6 8

Beyfortus

BeiGene

Phase 2

1 9

Haematopoietic growth factor

UUniversity College, London

Phase 3

1 10

TAA-T

CCatherine Bollard

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2032

Phase 3Recruiting

Hodgkin Lymphoma

NCT04685616

Clinical

Trials by Indication[1]

Hodgkin Lymphoma1 trial

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

Recruiting·UUniversity College, London·Phase 3·NCT04685616·1,042 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Haematopoietic growth factor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Haematopoietic growth factor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Haematopoietic growth factor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University College, London company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity College, London

Haematopoietic growth factor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2032

Trials by Indication[1]

Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News